A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Peter Langmuir, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
215 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Landeskrankenhaus Universitatsklinikum Graz
Graz, Austria
- Innsbruck University Hospital
Innsbruck, Austria
- Ordensklinikum Krankenhaus Der Barmherzigen Schwestern Linz
Linz, Austria
- Salzburger Universitatsklinikum
Salzburg, Austria
- Landeskrankenhaus Steyr
Steyr, Austria
- Allgemeines Krankenhaus Der Stadt Wien
Vienna, Austria
- Ulb Hospital Erasme
Brussels, Belgium
- Universitair Ziekenhuis Brussel
Brussels, Belgium
- Universitair Ziekenhuis Gent
Ghent, Belgium
- Hospital de Jolimont
Haine-st-paul, Belgium
- Az Groeninge Campus Kennedylaan
Kortrijk, Belgium
- Universitaire Ziekenhuis Leuven - Gasthuisberg
Leuven, Belgium
- Chu Ucl Namur University Hospital Mont-Godinne
Yvoir, Belgium
- Tom Baker Cancer Centre
Calgary, Alberta, Canada
- Cancercare Manitoba
Winnipeg, Manitoba, Canada
- Nova Scotia Health Authority/qeii Health Sciences Centre
Halifax, Nova Scotia, Canada
- Princess Margaret Cancer Center
Toronto, Ontario, Canada
- Mcgill University Health Centre Research Institute
Montreal, Quebec, Canada
- Peking Union Medical College Hospital
Beijing, China
- West China Hospital Sichuan University
Chengdu, China
- Fujian Cancer Hospital
Fuzhou, China
- Sun Yat-Sen Memorial Hospital Sun Yat-Sen University
Guangdong, China
- Sun Yat-Sen Memorial Hospital Sun Yat-Sen University
Guangzhou, China
- Shulan Hangzhou Hospital Co Ltd
Hangzhou, China
- the Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
- Heilongjiang Province Cancer Hospital
Harbin, China
- University of Science and Technology of China-First Affiliated Hospital (anhui Provincial Hospital)
Hefei, China
- Kunming 1st People'S Hospital
Kunming, China
- Jiangsu Province Hospital
Nanjing, China
- the Affiliated Hospital of Qingdao University
Shandong, China
- Xinhua Hospital
Shanghai, China
- Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine
Shanghai, China
- Zhongshan Hospital Fudan University
Shanghai, China
- Sichuan Cancer Hospital
Sichuan, China
- Tianjin Medical University Cancer Institute Hospital
Tianjin, China
- Hubei Cancer Hospital
Wuhan, China
- Tongji Hospital Huazhong University of Science and Technology
Wuhan, China
- Northern Jiangsu Peoples Hospital
Yangzhou, China
- Herlev Og Gentofte Hospital
Herlev, Denmark
- Docrates Cancer Center
Helsinki, Finland
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Jun 2019
- Primary completion
- 7 Jul 2025
- Completion
- 7 Jul 2025
- Last update posted
- 24 Aug 2025
- Registered enrollment
- 167
- Registry id
- NCT03656536
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.